S

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399

Watchlist Manager
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Watchlist
Price: 12.09 CNY -1.39% Market Closed
Market Cap: 17.7B CNY

Wall Street
Price Targets

Price Targets Summary
Shenzhen Hepalink Pharmaceutical Group Co Ltd

Wall Street analysts forecast Shenzhen Hepalink Pharmaceutical Group Co Ltd stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Shenzhen Hepalink Pharmaceutical Group Co Ltd is 7.55 CNY with a low forecast of 7.47 CNY and a high forecast of 7.77 CNY.

Lowest
Price Target
7.47 CNY
38% Downside
Average
Price Target
7.55 CNY
38% Downside
Highest
Price Target
7.77 CNY
36% Downside
Shenzhen Hepalink Pharmaceutical Group Co Ltd Competitors:
Price Targets
GLAXO
GlaxoSmithKline Pharmaceuticals Ltd
2% Downside
4568
Daiichi Sankyo Co Ltd
77% Upside
ROVI
Laboratorios Farmaceuticos ROVI SA
44% Upside
603456
Zhejiang Jiuzhou Pharmaceutical Co Ltd
19% Upside
605507
Guobang Pharma Ltd
46% Upside
688578
Shanghai Allist Pharmaceuticals Co Ltd
11% Upside
300765
CSPC Innovation Pharmaceutical Co Ltd
13% Downside
AUROPHARMA
Aurobindo Pharma Ltd
34% Upside

Revenue
Forecast

Revenue Estimate
Shenzhen Hepalink Pharmaceutical Group Co Ltd

For the last 8 years the compound annual growth rate for Shenzhen Hepalink Pharmaceutical Group Co Ltd's revenue is 11%. The projected CAGR for the next 3 years is 7%.

11%
Past Growth
7%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Shenzhen Hepalink Pharmaceutical Group Co Ltd

For the last 8 years the compound annual growth rate for Shenzhen Hepalink Pharmaceutical Group Co Ltd's operating income is 9%. The projected CAGR for the next 3 years is 20%.

9%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Net Income
Forecast

Net Income Estimate
Shenzhen Hepalink Pharmaceutical Group Co Ltd

For the last 8 years the compound annual growth rate for Shenzhen Hepalink Pharmaceutical Group Co Ltd's net income is 6%. The projected CAGR for the next 3 years is 14%.

6%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-18%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's stock price target?
Price Target
7.55 CNY

According to Wall Street analysts, the average 1-year price target for Shenzhen Hepalink Pharmaceutical Group Co Ltd is 7.55 CNY with a low forecast of 7.47 CNY and a high forecast of 7.77 CNY.

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Revenue forecast?
Projected CAGR
7%

For the last 8 years the compound annual growth rate for Shenzhen Hepalink Pharmaceutical Group Co Ltd's revenue is 11%. The projected CAGR for the next 3 years is 7%.

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Operating Income forecast?
Projected CAGR
20%

For the last 8 years the compound annual growth rate for Shenzhen Hepalink Pharmaceutical Group Co Ltd's operating income is 9%. The projected CAGR for the next 3 years is 20%.

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Net Income forecast?
Projected CAGR
14%

For the last 8 years the compound annual growth rate for Shenzhen Hepalink Pharmaceutical Group Co Ltd's net income is 6%. The projected CAGR for the next 3 years is 14%.

Back to Top